Gear up for the most awaited metaverse-based global event!
Don’t miss out on this enlightening conference focussed on Oncology domains by Ingenious E-Brain.
The virtual event “e-Brain OncoVision: Connecting the Dots in Cancer Care” is scheduled for February 15th (9:00AM EST) to February 16th, 2024 (5:30PM EST)
Featuring renowned speakers from leading biopharma companies & organizations, the…
Shots:
Exemplifying awareness campaign at its best with a hint of contemporary music, “It takes 2” by Boehringer Ingelheim and Eli Lilly is a noble initiative aimed at integrating UACR testing with eGFR for better screening of CKD
Noelle Bush, in an engaging conversation with PharmaShots, cites the growing incidences of CKD in the US.…
In pursuit of achieving data-driven excellence, PharmaShots came across Newstex. Soon, as a part of a collaboration PharmaShots and Newstex embarked on a journey to delivering high-quality and unerring content. Himanshu Sehgal, Director at PharmaShots, in a candid conversation with Newstex’s Head of Publisher Solutions, Laura Acosta. While sharing the origin story of PharmaShots, Himanshu…
PharmaShots is pleased to announce that we have entered into a new content partnership with Newstex, expanding the reach and impact of our insights across global professional and academic audiences.
This collaboration strengthens our mission to deliver high-quality, timely, and actionable biopharma and healthcare intelligence. By integrating PharmaShots’ curated industry updates into Newstex’s premium content distribution network, we aim to support researchers, analysts, students,…
Shots:
Diffuse large B-cell lymphoma remains the most common type of non-Hodgkin lymphoma. With limited therapeutic options for patients whose disease gets relapsed or refractory, AbbVie and Genmab’s TEPKINLY is one-of-a-kind monotherapy for adult patients with relapsed or refractory DLBCL
Post EC’s conditional approval, Julie Blaedel & Michael Moran engage in an enlightening conversation with…
Shots:
Following Qnovia’s recent partnership with the University of Virginia, Brian Quigley engages in a stimulating conversation with PharmaShots
The collaboration adds two assets, QN-05 for the treatment of pneumonia and QN-06 for the treatment of pulmonary infection caused by B. anthracis, to Qnovia’s portfolio
During a discussion of Qnovia's proprietary drug delivery platform RespiRx,…
Shots:
The oncology domain accounts for more than 50% of ongoing clinical trials. The global oncology drug market was valued at $185B in 2022 and is predicted to reach $205B by 2030 with a 13% CAGR
Targeted therapy targets specific genes and proteins to prevent them from growing and spreading. In 2022, the market size…
2023, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year.
Top 20 Radiopharma Companies Based on Market Cap
Shots:
Integrating scintigraphy with…
Shots:
Volker Wacheck sheds light on the recent approval of Lonsurf in combination with bevacizumab for patients with metastatic colorectal cancer
While sharing key insights from the pivotal P-III (SUNLIGHT) trial evaluating Lonsurf ± bevacizumab, Volker reveals that the combination drug is proven to prolong both OS and PFS along with QoL benefits and a…
Shots:
Amy Taneja, in a stimulating conversation with PharmaShots, shares the highlights of the Jada system, a vacuum-induced hemorrhage control device
Amy describes how the Jada system differs from traditional methods of controlling PPH while explaining how the system works
JADA, which is now being shipped to Chile, Hong Kong, Puerto Rico, New Zealand, and…

